• Johnson & Johnson disclosed new Phase 3 subgroup data for TREMFYA in Crohn’s disease patients with perianal fistulas.
• Results were being presented at the American College of Gastroenterology 2026 Annual Scientific Meeting.
• TREMFYA delivered consistent fistula remission outcomes across difficult-to-treat groups, including patients previously treated with biologics.
• Safety findings matched the drug’s established profile in Crohn’s disease, supporting its positioning in a high unmet-need complication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610121605PR_NEWS_USPR_____NY69911) on October 12, 2026, and is solely responsible for the information contained therein.